Sugi Predict

Sugi Predict / Compounds / SCHEMBL4275301

SCHEMBL4275301

SCHEMBL4275301

O=Cc1cc2ccncc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 3/20 0.56
▸ DAO P14920 2/20 0.53
▸ CCNT1 O60563 1/20 0.43
▸ CDK9 P50750 1/20 0.43
▸ HASPIN Q8TF76 1/20 0.43
▸ HRH4 Q9H3N8 1/20 0.41
▸ MAPT P10636 1/20 0.40
▸ SNCA P37840 1/20 0.40
▸ PDE3B Q13370 1/20 0.38
▸ PDE3A Q14432 1/20 0.38
▸ KDM5A P29375 1/20 0.38
▸ ERN1 O75460 1/20 0.38
▸ CHUK O15111 3/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ GABRP O00591 1/20 0.35
▸ GABRD O14764 1/20 0.35
▸ IKBKB O14920 1/20 0.35
▸ AURKA O14965 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ PIM1 P11309 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29423010 1.00 CYP2A6 (0.56) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL1160943 0.85 CYP2A6 (0.56) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL5832941 0.82 DAO (0.42) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL21601819 0.81 DAO (0.49) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL4268502 0.77 DAO (0.49) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL4268498 0.77 DAO (0.49) CYP2A6DAOCCNT1CDK9HASPIN
SCHEMBL30595155 0.75 CYP2A6 (0.52) CYP2A6
SCHEMBL29291831 0.74 FEN1 (0.47) CYP2A6DAOMAPTPDE3BPDE3A
Hydrochloric Acid SCHEMBL4283204 0.73 DAO (0.41) DAOCCNT1CDK9HASPINHRH4
Hydrochloric Acid SCHEMBL4283206 0.73 DAO (0.41) DAOCCNT1CDK9HASPINHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4705292-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2026-03-11 — — EP disclosed
EP-4558501-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF Arcus Biosciences, Inc. (US) 2025-05-28 — — EP disclosed
WO-2024233360-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-11-14 — — WO disclosed
US-12037342-B2 Substituted eneoxindoles and uses thereof GILEAD SCIENCES, INC. (US) 2024-07-16 — — US disclosed
WO-2024020034-A1 CBL-B INHIBITORS AND METHODS OF USE THEREOF ARCUS BIOSCIENCES, INC. (US) 2024-01-25 — — WO disclosed
US-20230183262-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF GILEAD SCIENCES, INC. 2023-06-15 — — US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 — — US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 — — EP disclosed
US-20160009716-A1 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2016-01-14 — — US disclosed
US-20160009716-A1 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS GLAXO GROUP LIMITED (GB) 2016-01-14 — — US disclosed
US-9127003-B2 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2015-09-08 — — US disclosed
US-9127003-B2 2-(azaindol-2-yl)benzimidazoles as PAD4 inhibitors GLAXO GROUP LIMITED (GB) 2015-09-08 — — US disclosed
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited a corporation 2015-06-25 — — US disclosed
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS Glaxo Group Limited a corporation 2015-06-25 — — US disclosed
WO-2014198848-A2 COMPOUNDS LYTIX BIOPHARMA AS (NO) 2014-12-18 — — WO disclosed
WO-2014198844-A1 PROTEIN KINASE INHIBITORS LYTIX BIOPHARMA AS (NO) 2014-12-18 — — WO disclosed
US-7608627-B2 I kappa B kinase inhibition; diabetes; (7-Chloro-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol; N-Benzyl-7-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxamide TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-27 — — US disclosed
US-20080064715-A1 6-Azaindole Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 CYP2A6 3412/4885DAO 2606/4885CCNT1 690/4885
US-20160009716-A1 2 - (AZAINDOL-2-YL) BENZ IMIDAZOLES AS PAD4 INHIBITORS PADI1, PADI4, PADI2 CYP2A6 2448/4885DAO 535/4885CCNT1 526/4885
US-20230183262-A1 SUBSTITUTED ENEOXINDOLES AND USES THEREOF HIPK1, HPGDS, HIPK3 CYP2A6 2430/4885DAO 1253/4885CCNT1 980/4885
US-12037342-B2 Substituted eneoxindoles and uses thereof HIPK1, HPGDS, HIPK3 CYP2A6 2430/4885DAO 1253/4885CCNT1 980/4885
US-20080064715-A1 6-Azaindole Compound RELA, NFKBIA, GPR119 CYP2A6 2824/4885DAO 1116/4885CCNT1 572/4885
US-20150175600-A1 2-(AZAINDOL-2-YL)BENZIMIDAZOLES AS PAD4 INHIBITORS PADI1, PADI4, PADI2 CYP2A6 2127/4885DAO 569/4885CCNT1 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.